<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245024</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000447144</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-UAZ04-2-02</secondary_id>
    <secondary_id>UARIZ-HSC-0553</secondary_id>
    <nct_id>NCT00245024</nct_id>
  </id_info>
  <brief_title>Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer</brief_title>
  <official_title>Phase IB Sulindac Study for Women at High Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of sulindac may prevent breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the effects of sulindac, to prevent breast&#xD;
      cancer, in women at high risk for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the partitioning of sulindac and its metabolites in women at high risk for&#xD;
           breast cancer by measuring drug and metabolite levels in nipple aspirate fluid (NAF)&#xD;
           after 6 weeks of therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine prostaglandin levels in the NAF of patients treated with this drug.&#xD;
&#xD;
        -  Determine if NAG-1 levels are induced in the NAF of patients treated with this drug.&#xD;
&#xD;
        -  Determine if C-reactive protein levels are reduced in the NAF of patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine if NAG-1 levels and/or karyometric features in ductal epithelial cells are&#xD;
           modulated in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study.&#xD;
&#xD;
      Patients undergo nipple aspirate fluid (NAF) collection. Patients are then randomized to 1 of&#xD;
      2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral sulindac once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral sulindac twice daily. In both arms, treatment continues&#xD;
           for 6 weeks in the absence of disease progression or unacceptable toxicity. All patients&#xD;
           then undergo a second NAF collection.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients (15 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sulindac and sulindac metabolite levels in nipple aspirate fluid (NAF) after 6 weeks of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostaglandin (PGE2) levels in NAF before and after 6 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAG-1 induction and C-reactive protein (CRP) reduction before and after 6 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of change and dose response of PGE2, NAG-1, and CRP in NAF before and after 6 weeks of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulindac</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Gail assessment score &gt; 1.7% risk for 5 years&#xD;
&#xD;
               -  History of lobular carcinoma in situ (pathology report required)&#xD;
&#xD;
               -  History of ductal carcinoma in situ (DCIS) (pathology report required)&#xD;
&#xD;
               -  History of breast cancer in ≥ 1 first-degree relative or history of BRCA1 or&#xD;
                  BRCA2 positivity not treated with oophorectomy or mastectomy (test report&#xD;
                  required)&#xD;
&#xD;
               -  History of breast cancer in ≥ 2 second-degree relatives&#xD;
&#xD;
               -  Any family history of breast cancer diagnosed prior to age 50&#xD;
&#xD;
               -  Personal history of breast cancer (invasive or DCIS) with 1 breast intact&#xD;
&#xD;
          -  Nipple aspirate fluid production ≥ 5 microliters&#xD;
&#xD;
          -  Negative mammogram for breast cancer within the past 10 months&#xD;
&#xD;
               -  Any suspicious breast masses must be examined by a clinical professional&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Pre- or postmenopausal&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No history of bleeding or clotting disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.0 times upper limit of normal&#xD;
&#xD;
          -  No indication of abnormal liver function&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No frequent, chronic, or moderate/severe gastric complaint&#xD;
&#xD;
          -  No upper gastrointestinal problems (e.g., symptoms of heartburn, dyspepsia, or&#xD;
             abdominal pain) requiring prescription or nonprescription medical remedies more than&#xD;
             once per week (on average)&#xD;
&#xD;
          -  No history of peptic ulcer or occult or gross intestinal bleeding&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reaction (e.g., urticaria, asthma, rhinitis) or gastric&#xD;
             intolerance attributed to compounds of similar chemical or biological composition to&#xD;
             sulindac&#xD;
&#xD;
          -  No history of allergy attributed to lidocaine, EMLA® cream, or xylocaine&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No more than 2-3 servings of alcohol per week during study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 months since prior chemotherapy for breast cancer (invasive or DCIS)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 6 months since prior hormonal therapy for breast cancer (invasive or DCIS)&#xD;
&#xD;
          -  No concurrent hormone-suppressing agents (e.g., tamoxifen or anastrozole)&#xD;
&#xD;
          -  No concurrent selective estrogen-receptor modulators&#xD;
&#xD;
          -  No concurrent aromatase inhibitors&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 6 months since prior radiotherapy for breast cancer (invasive or DCIS)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior breast duct-disrupting surgery (e.g., mastectomy) that would preclude&#xD;
             ductoscopy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior warfarin or other systemic anticoagulant&#xD;
&#xD;
          -  More than 4-6 weeks since prior nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No concurrent phenytoin or sulfonamides&#xD;
&#xD;
          -  No concurrent warfarin or other systemic anticoagulant&#xD;
&#xD;
          -  No other concurrent nonsteroidal anti-inflammatory drugs (including low-dose aspirin)&#xD;
&#xD;
          -  No concurrent large doses of supplements, vitamins (&gt; regular daily multivitamin)&#xD;
             and/or herbal medicines (e.g., echinacea, ginkgo biloba, Hypericum perforatum [St.&#xD;
             John's wort], or herbal tea)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Thompson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <name_title>H. H. Sherry Chow</name_title>
    <organization>Arizona Cancer Center at University of Arizona Health Science Center</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

